These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

394 related items for PubMed ID: 9679930

  • 1. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
    Mizutani Y, Yoshida O, Bonavida B.
    J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
    Mizutani Y, Okada Y, Terachi T, Yoshida O.
    J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
    [Abstract] [Full Text] [Related]

  • 3. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies.
    Konno R, Takano T, Sato S, Yajima A.
    Clin Cancer Res; 2000 Sep; 6(9):3576-80. PubMed ID: 10999747
    [Abstract] [Full Text] [Related]

  • 4. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    Mizutani Y, Yoshida O, Bonavida B.
    J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
    [Abstract] [Full Text] [Related]

  • 5. Circulating soluble Fas concentration in breast cancer patients.
    Ueno T, Toi M, Tominaga T.
    Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
    [Abstract] [Full Text] [Related]

  • 6. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
    Mizutani Y, Matsubara H, Yamamoto K, Nan Li Y, Mikami K, Okihara K, Kawauchi A, Bonavida B, Miki T.
    Cancer; 2004 Oct 15; 101(8):1794-802. PubMed ID: 15386310
    [Abstract] [Full Text] [Related]

  • 7. Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2.
    Yoshimura C, Nomura S, Kanazawa S, Kuwana M, Muramatsu M, Yamaguchi K, Fukuhara S.
    J Cancer Res Clin Oncol; 2002 Nov 15; 128(11):581-8. PubMed ID: 12458337
    [Abstract] [Full Text] [Related]

  • 8. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
    Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, Shariat SF.
    Cancer; 2006 Apr 15; 106(8):1701-7. PubMed ID: 16541433
    [Abstract] [Full Text] [Related]

  • 9. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
    Naumnik W, Izycki T, Ossolinska M, Chyczewska E.
    Exp Oncol; 2007 Jun 15; 29(2):132-6. PubMed ID: 17704746
    [Abstract] [Full Text] [Related]

  • 10. Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients.
    Gumus E, Erdamar S, Demirel G, Horasanli K, Kendirci M, Miroglu C.
    Int J Urol; 2004 Dec 15; 11(12):1070-7. PubMed ID: 15663677
    [Abstract] [Full Text] [Related]

  • 11. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
    Yutkin V, Pode D, Pikarsky E, Mandelboim O.
    J Urol; 2007 Dec 15; 178(6):2660-4. PubMed ID: 17945285
    [Abstract] [Full Text] [Related]

  • 12. Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus?
    Bijl M, van Lopik T, Limburg PC, Spronk PE, Jaegers SM, Aarden LA, Smeenk RJ, Kallenberg GG.
    J Autoimmun; 1998 Oct 15; 11(5):457-63. PubMed ID: 9802929
    [Abstract] [Full Text] [Related]

  • 13. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
    Słojewski M.
    Ann Acad Med Stetin; 2000 Oct 15; 46():217-29. PubMed ID: 11712306
    [Abstract] [Full Text] [Related]

  • 14. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients.
    Ugurel S, Rappl G, Tilgen W, Reinhold U.
    Clin Cancer Res; 2001 May 15; 7(5):1282-6. PubMed ID: 11350895
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer.
    Mizutani Y, Yoshida O, Ukimura O, Kawauchi A, Bonavida B, Miki T.
    Cancer Biother Radiopharm; 2002 Oct 15; 17(5):563-7. PubMed ID: 12470426
    [Abstract] [Full Text] [Related]

  • 16. Circulating soluble Fas in patients with breast cancer.
    Sheen-Chen SM, Chen HS, Eng HL, Chen WJ.
    World J Surg; 2003 Jan 15; 27(1):10-3. PubMed ID: 12557031
    [Abstract] [Full Text] [Related]

  • 17. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
    Perianayagam MC, Murray SL, Balakrishnan VS, Guo D, King AJ, Pereira BJ, Jaber BL.
    J Lab Clin Med; 2000 Oct 15; 136(4):320-7. PubMed ID: 11039853
    [Abstract] [Full Text] [Related]

  • 18. Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma.
    Mizutani Y, Wada H, Fukushima M, Yoshida O, Nakanishi H, Li YN, Miki T.
    Cancer; 2004 Feb 15; 100(4):723-31. PubMed ID: 14770427
    [Abstract] [Full Text] [Related]

  • 19. Serum soluble Fas level for detection and staging of prostate cancer.
    Furuya Y, Fuse H, Masai M.
    Anticancer Res; 2001 Feb 15; 21(5):3595-8. PubMed ID: 11848529
    [Abstract] [Full Text] [Related]

  • 20. [Cellular immune response of bladder tumor patients: effects of aging on cytotoxic activity against T24].
    Kato M.
    Hinyokika Kiyo; 1988 Aug 15; 34(8):1363-9. PubMed ID: 3195404
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.